ACMT Position Statement: Off-Label Prescribing during COVID-19 Pandemic.

Stolbach, Andrew I; Mazer-Amirshahi, Maryann; Marino, Ryan; Nelson, Lewis S; Sugarman, Jeremy

Stolbach, Andrew I; Mazer-Amirshahi, Maryann; Marino, Ryan; Nelson, Lewis S; Sugarman, Jeremy.

Stolbach AI; Johns Hopkins University School of Medicine, Baltimore, MD, USA. positionstatements@acmt.net.
Mazer-Amirshahi M; Department of Emergency Medicine, MedStar Washington Hospital Center and Georgetown University School of Medicine, Washington, DC, USA.
Marino R; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Nelson LS; Rutgers New Jersey Medical School, Newark, NJ, USA.
Sugarman J; Berman Institute of Bioethics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

J Med Toxicol ; 16(3): 342-345, 2020 Jul.

Article in English | MEDLINE | ID: covidwho-526931

Subject(s)

Coronavirus Infections/drug therapy; Emergency Medical Services/standards; Off-Label Use/statistics & numerical data; Off-Label Use/standards; Pneumonia, Viral/drug therapy; Practice Guidelines as Topic; Betacoronavirus/drug effects; COVID-19; Humans; Pandemics; SARS-CoV-2; United States; United States Food and Drug Administration

Keywords

COVID-19; Compassionate use; Coronavirus; Emergency use authorization; Expanded access; Off-label prescribing

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Practice Guidelines as Topic / Coronavirus Infections / Emergency Medical Services / Off-Label Use Type of study: Prognostic study Limits: Humans Country/Region as subject: North America Language: English Journal: J Med Toxicol Journal subject: Toxicology Year: 2020 Document Type: Article Affiliation country: S13181-020-00784-6

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google